Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Trial ID or NCT#

NCT05470283

Status

not recruiting iconNOT RECRUITING

Purpose

The goal of this clinical research study is to find the recommended dose of OBX-115 in combination with acetazolamide that can be given to patients with metastatic melanoma previously treated with immune checkpoint inhibitors. The safety and tolerability of the study drug combination will also be studied.

Official Title

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Allison Betof Warner, MD, PhD
Allison Betof Warner, MD, PhD
Cutaneous oncology specialist, Melanoma specialist, Medical oncologist
Assistant Professor of Medicine (Oncology)

Contact us to find out if this trial is right for you.

Contact

Claire Billman

View on ClinicalTrials.gov